Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents

Lukas Hauer, Jan Jambura, Daniel Hrusak, Miroslava Chalupova, Petr Posta, Stepan Rusnak, Vaclav Vyskocil

Background. Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious complication of antiresorptive and/or antiangiogenic therapy. It mainly affects oncological patients, however, it can occur in patients with metabolic bone diseases, although this is less frequent. These lesions not only significantly impair the quality of life but can also have impact on the treatment of any underlying disease. In some rare cases MRONJ can be life-threatening. There is still no ideal consensus for treatment, though surgical therapy has been mostly preferred in recent years.

Materials and Methods. A monocentric retrospective evaluation of surgical therapy of MRONJ in osteoporotic patients, treated in the time period 3/2014-3/2018 using the uniform department-specific protocol.

Results. 26 osteoporotic patients with 32 MRONJ lesions of stage 1 (9%), stage 2 (75%) and stage 3 (16%) were treated surgically. The maxilla: mandibula ratio was 1:2.2, in 19% of patients there was multiple jaw involvement. 69.2% of patients had received bisphosphonates, 15.4% denosumab and 15.4% had a history of both types of antiresorptive treatment. Complete healing was observed in all patients, in 9% of cases by secondary intention in the mean period of 6 weeks. The mean follow-up was 20.5 months.

Conclusion. The presented protocol for surgical therapy was effective in the management of all MRONJ stages in the osteoporotic patients described here. The surgery is indicated as an early treatment to prevent complications and the progression of the lesions. It leads to improvement in quality of life and option to resume antiresorptive therapy if interrupted.

Key words: osteonecrosis of the jaw, MRONJ, antiresorptive drugs, osteoporosis, fluorescence-guided surgery

INTRODUCTION

Osteoporosis is a metabolic bone disease highly prevalent in the developed countries (over 200 million people suffering from osteoporosis around the globe) (ref.1). It is defined as a progressive chronic disease of the skeleton characterized by excessive bone loss in its inorganic and organic component with microarchitectural disorders resulting in a decrease in bone mechanical resistance and increased risk of fractures2. Approximately 7% of the population of the Czech Republic suffer from osteoporosis, ie about 700,000 people with 50,000 registered osteoporotic fractures annually2. Primary osteoporosis is the most common form of the disease and includes postmenopausal osteoporosis and senile osteoporosis. Secondary osteoporosis has a clearly definable causal factor other than menopause and aging and it is caused by certain medical conditions or pharmacotherapy2. Currently, the mainstay forms of antiresorptive therapy for osteoporosis are bisphosphonates (mostly alendronate and ibandronate) and denosumab. These drugs inhibit osteoclast mediated bone resorption and prevent fractures1.

A rare adverse effect of antiresorptive treatment in patients with osteoporosis but especially in patients with malignancies is Medication-Related Osteonecrosis of the Jaw (MRONJ). According to a position paper published by the American Association of Oral and Maxillofacial Surgeons (AAOMS) in 2014, MRONJ may be considered in patients who fulfill all of the following characteristics. Exposed or probable bone through an intraoral/extraoral fistula(e) in the maxillofacial region without resolution for longer than 8 weeks in patients with history of antiresorptive and/or antiangiogenic therapy who have not received radiation therapy to the jaws and who are without obvious metastatic disease in this area1. In contrast, cancer patients, who use high doses of antiresorptive agents to prevent skeletal-related events, osteoporosis patients are considered to be significantly less at risk for the development of MRONJ (less than 10% of MRONJ cases) (ref.3). However, even in this group, MRONJ may have a severe
complicated course, significantly impairing the quality of life through pain, halitosis, teeth loss, affection of the trigeminal nerve branches with sensitivity disturbances, fistula formation with pus exudation, pathological fracture of mandible, oroantral or oronasal communication, deep neck space infection and chronic rhinosinusitis. In these patients, MRONJ may be perceived as worse than the underlying disease.

The life expectancy of osteoporosis patients is significantly longer than patients with an advanced stage of malignant disease, therefore, complete healing of these lesions with relief of all symptoms is the ultimate and highly desirable goal of the therapy. In the majority of patients, the symptoms of MRONJ, such as pain and those caused by infection, may be improved temporarily using conservative therapy (primarily antibacterial mouth rinses and systemic antibiotics), particularly at an early stage of disease\textsuperscript{5-7}. However, complete mucosal coverage is rarely achieved. In addition, the healing is prolonged and difficult to predict\textsuperscript{1}. A non-surgical approach is therefore rather more palliative and has greater importance in cancer patients\textsuperscript{5,6}. Recently, a radical surgical therapy seems to have the most successful outcomes in terms of complete mucosal closure at any stage of disease\textsuperscript{7}. The principle of this treatment is the complete removal of necrotic bone, smoothing of sharp bony edges and meticulous tension-free primary wound closure by adjacent soft tissues accompanied by perioperative antibiotics administration\textsuperscript{7}. In some cases continuity resections including jaw reconstruction are required. Surgical techniques are still not standardized and they mostly depend on a surgeon’s skills and experience\textsuperscript{5}. Subsequent dental and prosthetic reconstruction enables restoration of the affected functions and such patients can continue with antiresorptive therapy if interrupted\textsuperscript{5}.

**MATERIALS AND METHODS**

This was a monocentric retrospective evaluation of the surgical therapy of MRONJ in osteoporotic patients, treated at the Department of Oral and Maxillofacial Surgery (University Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic) from 3/2014-3/2018. The diagnostic criteria and staging of MRONJ was in the line with the AAOMS guidelines (2014) (ref.\textsuperscript{1})

Stage 0 No clinical evidence of necrotic bone, but non-specific symptoms and/or clinical and/or radiographic findings for more than 8 weeks, which could not be explained otherwise

Stage 1 Exposed and necrotic bone, or fistula(e) that probed to bone, in patients who were asymptomatic and had no evidence of infection

Stage 2 Exposed and necrotic bone, or fistula(e) that probes to bone, associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage

Stage 3 as well as the 2\textsuperscript{nd} stage and one or more of the following: exposed and necrotic bone extending beyond the region of the alveolar bone, pathological fracture, extra-oral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the mandible or sinus floor.

The uniform surgical protocol for the treatment of MRONJ was used. All surgical procedures were performed by the same specialized Oral and Maxillofacial Surgeons. Monitored parameters of this study were: gender, age, type of osteoporosis, concomitant risk factors, initiating factors, localization and stage of MRONJ, type and duration of antiresorptive therapy (till the time of MRONJ diagnosis) and outcomes of surgical therapy.

**The protocol of surgical therapy**

All osteoporotic patients with MRONJ of 1st., 2nd and 3rd stage were indicated for surgical treatment. First, they were referred to their osteologist / rheumatologist in order to report the adverse effect of antiresorptive therapy to the State Institute for Drug Control. No drug holiday in cases of receiving bisphosphonates was required. In patients treated with denosumab, surgery was delayed for at least 3 months after the last dose, and further administration of denosumab was initiated 2-3 months after complete healing occurred. The changes in an antirheumatic therapy (glucocorticosteroids, cytostatics, targeted therapy, etc.) due to the planned surgery and anticipated healing disruptions were left to be resolved by the rheumatology specialist. All patients underwent cone beam computed tomography (CB CT) or CT as a part of pre-operative planning.

The primary goal in MRONJ cases with symptoms caused by infection (2nd, 3rd stage) or accompanied by deep neck space infections was to treat these conditions before the treatment of osteonecrosis (antibiotics, incision, drainage). If the purulent discharge was a result of the separation of bone sequestrum, surgery was postponed till there was decrease in symptoms of infection and sequestrectomy was performed. Patients with MRONJ-induced maxillary or more extensive bacterial rhinosinusitis received nasal decongestant perioperatively (for one week) followed by nasal corticosteroids (long-term use). According to the extent of lesions, their localization, disease stage and compliance of patients, a surgery was planned including either local or general anesthesia, always during a short-term hospitalization. Patients underwent standard preoperative examinations. The fluorescence of tetracycline antibiotic bound in a bone tissue visualized intraoperatively during exposure of VELscope (Visually Enhanced Lesion Scope) light of 400-460 nm wavelength was used to distinguish between viable and necrotic bone. Patients received doxycycline 100 mg every 24 h perorally for 7 days prior to the surgery. The day before the operation, the doxycycline was discontinued and patients started to use antibiotic prophylaxis, namely co-amoxicillin intravenously or perorally in the usual dosage for 10-14 days (until healing occurred). In the case of allergy to penicillin, clindamycin was administered intravenously or perorally or doxycycline was continued.

In the cases of extensive lesions without sequestration, radical removal of necrotic bone was performed by
RESULTS

32 MRONJ lesions in 26 osteoporotic patients were treated surgically.
Fig. 1. MRONJ emerged after 6 years exposure to oral ibandronate in 53-year-old women.

Fig. 2. Orbital cellulitis as the complication of MRONJ-induced maxillary rhinosinusitis and ethmoiditis in the patient from Fig. 1.

ication (corticosteroids, leflunomide, methotrexate, azathioprine, etanercept).

Outcomes of the MRONJ surgical therapy

Deep neck space infections (2 patients) were successfully managed with extraoral incisions, pus drainage and antibiotic therapy. The cases of rhinosinusitis were resolved with the removal of necrotic bone as an inducing factor and conservative therapy (nasal decongestants and corticosteroids). Only in one patient with orbital cellulitis a functional endoscopic sinus surgery with middle meatal antrostomy and ethmoidectomy was necessary. The orbital infection was managed without necessity of other surgical approaches into the orbit and complete healing with no functional morbidity was achieved only by antibiotic therapy. Two residual cysts adjacent to MRONJ lesions were removed (extirpated) concomitantly with a MRONJ surgery. Surgical treatment of 28 MRONJ lesions (87.5%) was performed under local anesthesia and in remaining 4 cases (12.5%) under general anesthesia. A mylohyoid flap and a buccal fat pad flap were used in 9 and 4 cases respectively (in 3 cases to cover the oroantral communication) (Fig. 3). The pathological mandibular fracture was managed with a necrotic bone removal and
a load-bearing osteosynthesis from an intraoral and sub-mandibular approach. A mandibular reconstruction plate as an osteosynthesis device was used. It was prebended on the individual jaw model created by 3 D printer using patient’s CT data (Fig. 4). A complete healing (the achievement of complete mucosal closure) was observed in all patients (100%), in 9.4% of cases (n=3) by secondary intention in the mean period of 6 weeks. No second surgery to achieve complete healing was necessary. The rest of the lesions (n=29; 90.6%) healed by primary intention in two weeks. Further course was uneventful. The mean follow-up was 20.5 months.

**DISCUSSION**

Patients receiving antiresorptive medication (bisphosphonates, denosumab), anti-angiogenic drugs (e.g. bevacizumab, aflibercept) and tyrosine kinase inhibitors (e.g. sunitinib, imatinib) are at the risk of development of MRONJ (ref.4). The concurrent use of these agents with or without additional immunosuppressants may increase the odds for emergence of these lesions, shorten the latency period and also contribute to more serious clinical course of this disease4,7,9.
The risk of MRONJ emergence is mostly dependent on the type of antiresorptive drugs, route of administration, dosage and duration of treatment. When compared to cancer patients receiving high-dose regimens of antiresorptive therapy, the risk of MRONJ for patients with osteoporosis exposed to medications of low doses is about 100 times smaller. The prevalence of MRONJ in osteoporotic patients treated with oral bisphosphonates was reported up to 0.1% with an increasing tendency for more than 4 years of drug exposure. Patients who are under treatment with corticosteroids and/or immunosuppressants may have a higher risk for developing MRONJ even if the bisphosphonates duration is less than 4 years. The prevalence associated with zolendronate or denosumab treatment in osteoporotic patients was reported 0.017% and 0.3% respectively. Although MRONJ is a rare disease in osteoporotic patients, the real number of affected patients appears to be higher than the published incidence, which is best explained by large population of osteoporotic patients exposed to antiresorptive agents. Furthermore, the number of osteoporosis patients is steadily enlarging.

The pathogenesis of MRONJ is probably multifactorial and it has not yet been fully clarified. None of the known etiopathogenetic factors itself is able to explain the emergence of these lesions. The main pathogenetic mechanism is a drug-induced disturbance of bone homeostasis caused by afflicting cells of a monocyte-macrophage lineage. It results in decrease of bone re-modeling (an atrophy caused by afflicting cells of a monocyte-macrophage lineage). Various concomitant factors have an immunosuppressive effect of some of drugs may also contribute to MRONJ pathogenesis. Various concomitant risk factors have been published to date with varying degree of significance indicating that this issue is not yet well understood. Only an immunodeficient state of patient was monitored as the main concomitant risk factor in this study (e.g. immunosuppressive medication, diabetes mellitus etc.).

According to the largest systematic review of 680 MRONJ cases in osteoporotic patients, these lesions mainly affected women (93.5%, male to female ratio 1:14.4) and the mean age of patients was 69.7 ± 5.2 years. Bisphosphonates were administered mainly orally in 86.7% of cases and the most often received drug was alendronate (72.6%). A combination of more than one type of antiresorptive agent was reported only in 4% of cases. Corticosteroids or immunosuppressants were the most common concomitant medications in MRONJ. The bisphosphonates treatment was typically long term with the average duration of intake 51.9 ± 18 months. The most common initiating event was tooth extraction (48.5%). Lesions occurred most frequently in the mandible (70.6%), followed by maxilla (27.2%) and both jaws (2.2%) and were most often classified as stage 2 (50.5%) (ref.5).

In the present study, there was a slightly higher age of affected patients and a significantly higher proportion of patients were treated with more than one type of antiresorptive agent (42.3% versus 4%). A smaller proportion of patients received bisphosphonates orally (65.4% versus 86.7%) and a longer latency period was identified (73.1 ± 38.0 months versus 51.9 ± 18 months). Other characteristics were consistent with the referred study.

Treatment options for MRONJ are still under debate. There is a lack of well-designed, prospective, randomized clinical trials and no evidence-based guidelines are available. When evaluating the outcomes of MRONJ treatment, conservative therapy leads to complete healing in only a small percentage of cases (18-23%) (ref.17,18). A very low likelihood of resolving of these lesions is especially in advanced disease (stage 3) (ref.5). The outcome of a predominantly long-lasting healing process is difficult to predict. With increasing experience over the last ten years, more evidence has emerged to support the surgical approach as the most effective management of MRONJ in terms of complete healing. The success rate 59-100% was reported, with mostly more than 90% in recent years.

Some authors still recommend surgical treatment only for the higher symptomatic stages of the disease or in cases of conservative therapy failure. But surgery seems to be effective for the treatment of MRONJ at any disease stage. It also offers the best condition for healing regardless of the type of a drug that induced osteonecrosis of the jaws. Based on these findings and considering life expectancy of osteoporotic patients, surgical therapy should be the first choice for all MRONJ stages with the aim of complete healing. In addition, better outcomes are achieved compared to cancer patients. Some authors reported relatively good effect of the conservative therapy of MRONJ in osteoporotic patients, but particularly early stages were included. In contrast, the surgical therapy usually achieves shorter healing period, better predictability and success rate even in advanced disease. Surgery should be indicated as an early treatment to prevent complications and progression of lesions. A bacterial embolism in the internal jugular vein after a MRONJ-induced submandibular abscess resulting in bacterial sepsis, multi-organ failure syndrome and death in an osteoporotic patient receiving alendronate was published in the literature. It should be noted that this is a rare complication.

The surgery should preserve viable bone and soft tissues as much as possible. In our opinion and according to some other authors, no preventive extension with safety margins is necessary. Distinguishing between viable and necrotic bone is challenging and intraoperative visualization of fluorescent patterns of viable and nonviable bone (fluorescence-guided surgery) may improve surgical outcomes. It requires an experienced surgeon familiar with this technique. Viable bone shows bright greenish fluorescence during this examination, while necrotic bone has none or only pale fluorescence. A reddish fluorescence is associated with a bacterial colonization or infection of
nonvital bone and is not conditioned by a doxycycline exposure. Various protocols of doxycycline administration have been published including a single intravenous drug administration. In addition, auto-fluorescence-guided bone surgery probably shows comparable success rates to tetracycline fluorescence-guided surgery.

A wound closure in two layers, which is very feasible only in the distal areas of both jaws, is beneficial. The mylohyoid flap and buccal fat pad flap are reported as the procedures of choice in this indication. In our experience, the buccal fat pad flap is preferred in all large lesions of osteonecrosis in the premolar and molar maxillary area, not only to cover oranostral communication. This low-risk and high-yield approach promote the healing process by a rich vascularization of the flap and an abundant source of adipose-derived adult stem cells. The two-layers wound closure provides low failure rates of mucosal coverage and also mechanic protection of the affected area for possible rehabilitation by removable prosthesis. Another advantage is minimal donor site morbidity.

There is no evidence that a drug holiday facilitates healing in surgical sites and safety of this approach as well as optimal timing have not been verified. Even though some physicians recommend an interruption of antiresorptive treatment. According to pharmacokinetic properties of denosumab, which has a reversible effect on bone remodeling, drug holiday could have some respond in terms of better healing. Considering the dosing of denosumab (60 mg every 6 months) in osteoporotic patients, the surgical therapy of MRONJ is possible without disturbing the drug administration cycle (i.e., in the middle of the cycle).

CONCLUSION

The presented protocol for surgical therapy is effective in the management of all MRONJ stages in osteoporotic patients. The surgery is indicated as an early treatment to prevent complications and the progression of lesions. It leads to an improvement in the quality of life and it offers the option of resuming antiresorptive treatment if interrupted.

Author contributions: LH, JJ: manuscript writing; LH, MCH, SR, PP: data collection, data analysis; LH, JJ: study design; LH, DH, VV: final approval.

Conflict of interest statement: None declared.

REFERENCES

1. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2(6):285-9.
2. Sotornik I. Osteoporóza – epidemiologa a patogeneze. Vnitř Lék 2016;62(12, Suppl 6):6584-7.
3. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniofac Surg 2017;45(9):1493-302.
20. Holzinger D, Seemann R, Klug C, Ewers R, Millesi G, Baumann A, Wutzl A. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol 2013;49(1):66-70.
21. Stockmann P, Vainikkaris E, Wehrhan F, Seiss M, Schwarz S, Spirewald B, Neukam FW, Nkenke E. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010;18(4):449-60.
22. Stockmann P, Burger M, von Wilmowsky C, Ebker T, Lutze R, Baersachs A, Nkenke E, Neukam FW, Wehrhan F. The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw—results of a clinical case series with an average follow-up of 20 months. Clin Oral Investig 2014;18(4):1299-304.
23. Carlsson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(S Suppl):85-95.
24. Assaf AT, Zrnc TA, Riecke B, Wikner J, Zustin J, Friedrich RE, Heiland C. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw. J Craniofac Surg 2018;46(7):1153-8.
25. Voss PJ, Joshi Oshero J, Kovalova-Müller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, Lemound J, Metzger MC, Schmelzeisen R. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniofac Surg 2012;40(8):719-25.
26. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg 2010;39(3):251-5.
27. Otto S, Ristow O, Pache C, Troeltzsch M, Fliefel R, Ehrenfeld M, Pautke C. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. J Craniofac Surg 2016;44(8):1073-80.
28. Otto S, Baumann S, Ehrenfeld M, Pautke C. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. J Craniofac Surg 2013;41(7):694-8.
29. Hoeffert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course and therapeutic outcomes of operatively and non-operative ly managed patients with denosumab-related osteonecrosis of the jaw (DRONJ). J Craniofac Surg 2017;45(4):e570-8.
30. Pichardo SE, van Merkestyen JP. Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122(3):287-91.
31. Lescous P, Grabar S, Abi Najm S, Carrel JP, Lombardi T, Saffar JL, Samson J. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. Clin Oral Investig 2014;18(2):391-9.
32. Hayashida S, Soutome S, Yamamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, Kiriti T, Nakahara H, Shinohara M, Umeda M. Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res 2017;32(10):2022-9.
33. Baguminy T, Peydró A, Calvo J, Leopoldo M, Jiménez Y, Bagan L. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Oral Dis 2016;22(4):324-9.
34. Nisi M, Karapetis D, Gennai S, Ramaglia L, Graziani F, Gabriele M. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. J Craniomaxillofac Surg 2018;46(7):157-66.
35. Kaehling Ch, Streckbein P, Schmermund D, Henrich M, Burchert D, Gattenloehner S, Howaldt HP, Wilbrand JF. Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw. J Craniofac Surg 2014;42(7):1203-6.
36. Ristow O, Otto S, Geiß C, Kehl V, Berger M, Troeltzsch M, Koerdt S, Hohlweg-Majert B, Freundspurger C, Pautke C. Comparison of autofluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study. Int J Oral Maxillofac Surg 2017;46(2):157-66.
37. Melville JC, Tursun R, Shum JW, Young S, Hanna IA, Marx RE. A technique for the treatment of oral-antral fistulas resulting from medication-related osteonecrosis of the maxilla: the combined buccal fat pad flap and radical sinusotomy. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;122(3):287-91.
38. Gallego L, Junquera L, Pelaz A, Hernando J, Megias J. The use of pedicled buccal fat pad combined with sequestrectomy in bisphosphonate-related osteonecrosis of the maxilla. Med Oral Patol Oral Cir Bucal 2012;17(2):e236-41.
39. Berrone M, Florindl FJ, Carbone V, Aldiano C, Pentenero M. Stage 3 Medication-Related Osteonecrosis of the Posterior Maxilla: Surgical Treatment Using a Pedicled Buccal Fat Pad Flap: Case Reports. J Oral Maxillofac Surg 2015;73(11):2082-6.
40. Rotaru H, Kim MK, Kim SG, Park YW. Pedicled buccal fat pad flap as a reliable surgical strategy for the treatment of medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 2015;73(3):437-42.
41. Mücke T, Koerdt S, Jung M, Mitchell DA, Wolff KD, Kesting MR, Loeffelbein DJ. The role of mylohyoid flap in the treatment of bisphosphonate-related osteonecrosis of the jaws. J Craniomaxillofac Surg 2016;44(4):369-73.
42. Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116(6):e437-42.